Provided by Tiger Trade Technology Pte. Ltd.

Viridian Therapeutics, Inc.

23.03
-0.1300-0.56%
Post-market: 23.030.00000.00%19:30 EDT
Volume:998.38K
Turnover:22.99M
Market Cap:2.61B
PE:-6.66
High:23.34
Open:23.02
Low:22.89
Close:23.16
52wk High:34.29
52wk Low:13.18
Shares:113.29M
Float Shares:101.00M
Volume Ratio:1.15
T/O Rate:0.99%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4579
EPS(LYR):-3.3245
ROE:-65.74%
ROA:-30.16%
PB:4.63
PE(LYR):-6.93

Loading ...

Viridian Therapeutics Exec Says Five Infusions of Its Thyroid Eye Disease Drug Lumvoa are Priced Roughly in Line with Eight Infusions of Amgen’s Tepezza - Conf Call

THOMSON REUTERS
·
Jun 29

Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN) and Fortrea Holdings Inc. (FTRE)

TIPRANKS
·
Jun 29

U.S. Stocks on the Move-spacex, Charter

Reuters
·
Jun 29

US Stocks-wall St Climbs as Mideast Tensions Ease, Comcast Surges on Spin-off Plan

Reuters
·
Jun 29

Stock Market Today: Dow Jones, S&P 500 Futures Gain As Trump Admin Says US, Iran Will 'Stand Down'—Verizon, HP, Universe Pharmaceuticals In Focus

Benzinga Earnings
·
Jun 29

Viridian Therapeutics Shares up 10.8% Premarket After U.S. FDA Greenlights Co's Thyroid Eye Disease Drug

THOMSON REUTERS
·
Jun 29

Concentrix, AeroVironment And 3 Stocks To Watch Heading Into Monday

Benzinga Earnings
·
Jun 29

Why Viridian Therapeutics (VRDN) Is Up 7.6% After FDA Clears First All‑Stage Thyroid Eye Drug

Simply Wall St.
·
Jun 29

Analysts Are Bullish on These Healthcare Stocks: Viridian Therapeutics (VRDN), Genfleet Therapeutics (Shanghai), Inc. Class H (HK:2595)

TIPRANKS
·
Jun 28

US FDA Greenlights Viridian's Eye Disease Drug

Reuters
·
Jun 27

Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease

THOMSON REUTERS
·
Jun 27

Viridian’s VRDN-003 Thyroid Eye Disease Trial Reaches Completion, Resetting the Risk/Reward for Investors

TIPRANKS
·
Jun 26

Viridian Therapeutics (VRDN) Stock Could Be 84.84% Below Fair Value After Institutional Buying

Simply Wall St.
·
Jun 19

Analysts Offer Insights on Healthcare Companies: BioAge Labs, Inc. (BIOA) and Viridian Therapeutics (VRDN)

TIPRANKS
·
Jun 17

Viridian Therapeutics shareholders elected Class II directors at annual meeting

Reuters
·
Jun 03

How Investors May Respond To Viridian Therapeutics (VRDN) Debt Repayment And WuXi Manufacturing Pact

Simply Wall St.
·
May 31

Viridian Therapeutics prepays Hercules loan, repays about $55.1 million

Reuters
·
May 29

Viridian Therapeutics management to present at Jefferies Global Healthcare Conference

Reuters
·
May 27

Viridian Therapeutics signs WuXi Biologics manufacturing pact for veligrotug commercial supply

Reuters
·
May 27

Viridian Therapeutics Inc - WuXi Biologics to Manufacture and Supply Veligrotug for Viridian Therapeutics - SEC Filing

THOMSON REUTERS
·
May 27